Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 receptor agonists are supported by large multi-center randomized controlled trials published in the New England Journal of Medicine. The STEP 1, SURMOUNT-1, SCALE, and SELECT trials collectively establish the clinical efficacy and cardiovascular safety profile of semaglutide, tirzepatide, and liraglutide for obesity treatment.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Semaglutide (Ozempic for type 2 diabetes, Wegovy for chronic weight management) produced a mean weight reduction of 15.3% over 68 weeks in the STEP 1 randomized controlled trial (Wilding et al., NEJM 2021, n=1,306). Prescribed via weekly subcutaneous injection with physician-guided dose escalation over 16–20 weeks.
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) produced a mean weight reduction of 22.5% over 72 weeks in the SURMOUNT-1 randomized controlled trial (Jastreboff et al., NEJM 2022, n=2,539) — the highest efficacy among any FDA-approved obesity pharmacotherapy to date.
Liraglutide 3.0 mg (Saxenda) produced a mean weight loss of 8.4% over 56 weeks in the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015), with 63.2% of participants achieving ≥5% body weight reduction. Administered via daily subcutaneous injection; the longest safety record among GLP-1 agents.
The clinical case for FDA-approved GLP-1 receptor agonists is established by large-scale placebo-controlled trials in the New England Journal of Medicine, covering 56–72 week treatment periods:
GLP-1 receptor agonists are not controlled substances under DEA scheduling. They may be prescribed via telehealth consultation under Wyoming law after a valid clinical evaluation by a WY-licensed physician.
Wyoming authorizes licensed physicians to prescribe FDA-approved medications via telehealth after establishing a valid patient-physician relationship through a synchronous or asynchronous online consultation. WY-licensed physicians in our network comply with all applicable Wyoming Medical Practice Act provisions governing telehealth consultations, electronic prescribing, and controlled-substance rules.
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not controlled substances under DEA scheduling. They may be prescribed through a standard telehealth consultation under Wyoming law without requiring an in-person visit. All consultations use HIPAA-compliant encrypted platforms. Prescriptions are transmitted electronically to licensed US pharmacies, which then arrange home delivery to Uinta addresses.
Residents of Uinta, Wyoming can complete the entire consultation process online. Board-certified WY-licensed physicians review your clinical profile and, when medically appropriate, issue a prescription for an FDA-approved GLP-1 medication.
Complete a structured clinical intake covering your BMI, weight history, metabolic markers, current medications, and relevant comorbidities (type 2 diabetes, hypertension, cardiovascular disease). This intake provides the prescribing physician with the clinical context required under Wyoming telehealth guidelines to conduct a valid evaluation.
A board-certified, WY-licensed physician reviews your intake and conducts a HIPAA-compliant telehealth consultation. The physician evaluates your eligibility based on FDA-approved indications (BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity) and selects the most clinically appropriate GLP-1 medication for your individual profile.
If a prescription is issued, it is transmitted electronically to a licensed US pharmacy. Medication is shipped in temperature-controlled packaging to your Uinta address, typically within 3–5 business days. Cold-chain requirements for injectable GLP-1 medications are maintained throughout the shipping process per USP storage standards.
Your prescribing physician schedules follow-up consultations to monitor weight response, assess tolerability, and adjust dosing per the published escalation schedules for each medication. Typical escalation for semaglutide spans 16–20 weeks; tirzepatide escalation spans 20 weeks to maximum dose. Ongoing monitoring is documented in your HIPAA-compliant patient record.
In-person weight management clinics in Uinta often have wait times of 4–12 weeks for an initial appointment. Telehealth consultations with WY-licensed physicians provide the same standard of clinical care — including a full medical history review, FDA-approved medication selection, and documented follow-up — from any location in Uinta.
All GLP-1 prescriptions issued through this platform come from licensed WY physicians following the same FDA-approved indications and prescribing guidelines that apply in an in-person clinic setting. Medications are sourced exclusively from licensed US pharmacies with verified supply chains.
Residents of communities near Uinta can also access GLP-1 telehealth care from board-certified WY-licensed physicians through this platform.
Board-certified physicians serve residents across all major cities in Wyoming through HIPAA-compliant telehealth consultations.
Licensed GLP-1 telehealth physicians serve patients across all major US cities, connecting you with board-certified care regardless of your location.
Local weight loss and GLP-1 providers serving the Uinta, WY area, based on Google Business listings.
3929 Wall Ave, South Ogden, UT 84405
(801) 393-3586
4.9/5 ★ (115 reviews)
Visit website →6028 S Ridgeline Dr STE 204, Ogden, UT 84405
(801) 896-3710
4.9/5 ★ (68 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes. Wyoming authorizes licensed physicians to prescribe medications — including GLP-1 receptor agonists — via telehealth after a clinically appropriate online evaluation. GLP-1 medications are not controlled substances, so no in-person visit is required under Wyoming telehealth statutes.
FDA-approved options available through telehealth in Wyoming include semaglutide (Ozempic for type 2 diabetes; Wegovy for chronic weight management), tirzepatide (Mounjaro for type 2 diabetes; Zepbound for obesity), and liraglutide (Saxenda for weight management). Your WY-licensed physician selects the most appropriate medication based on your BMI, comorbidities, and medical history.
Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). Saxenda (liraglutide) is approved under the same BMI thresholds. Your physician conducts a clinical evaluation to confirm you meet the approved criteria.
The SURMOUNT-1 trial showed tirzepatide achieves greater mean weight loss (22.5%%) than semaglutide in the STEP 1 trial (15.3%%). However, the prescribing decision depends on your individual clinical profile: existing type 2 diabetes diagnosis, cardiovascular risk factors, insurance coverage, and tolerability history. Your physician will document their clinical rationale for the selected medication.
Your WY-licensed prescribing physician schedules follow-up consultations to review your weight response, adjust dosing per published escalation schedules, and assess tolerability. Side effects such as nausea, vomiting, or gastrointestinal symptoms are common during dose escalation and are documented and managed as part of your ongoing care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
